Select publications

Crawford ED et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321(7):419-24. Abstract

Crawford ED et al. Combined androgen blockade: Leuprolide and flutamide versus leuprolide and placebo. Semin Urol 1990;8(3):154-8. Abstract

Eisenberger MA. A multicenter comparison of docetaxel given weekly or every three weeks + prednisone with mitoxantrone + prednisone in patients with hormone-refractory prostate cancer: Study TAX-327. Presentation. ASCO 2004;Abstract 4.

Eisenberger MA et al. A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). Proc ASCO 2004;Abstract 4.

Messing EM et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341(24):1781-8. Abstract

Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20. Abstract

Petrylak DP et al. SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA). Proc ASCO 2004;Abstract 3.

Smith MR et al. Association between androgen deprivation therapy and fracture risk: A populationbased cohort study in men with non-metastatic prostate cancer. Proc ASCO 2004;Abstract 4507.